<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01609127</url>
  </required_header>
  <id_info>
    <org_study_id>TOB206</org_study_id>
    <nct_id>NCT01609127</nct_id>
  </id_info>
  <brief_title>Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer</brief_title>
  <official_title>A Randomized, Phase II Study of Tesetaxel Once Every 3 Weeks Versus Tesetaxel Once Weekly for 3 Weeks Versus Capecitabine Twice Daily for 14 Days as First-line Therapy for Subjects With Locally Advanced or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genta Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genta Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to compare the efficacy and safety of tesetaxel administered&#xD;
      once every 3 weeks in a 21-day cycle, tesetaxel administered once weekly for 3 consecutive&#xD;
      weeks in a 28-day cycle, and capecitabine administered twice daily for 14 consecutive days in&#xD;
      a 21-day cycle.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>4 months after the date of randomization of the last patient, which is estimated will occur 16 months after the first patient is randomized</time_frame>
    <description>the percentage of patients with a confirmed complete or partial response, as defined in the revised Response Evaluation Criteria in Solid Tumors (revised RECIST [Version 1.1])</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>12 months after the date of randomization of the last patient, which is estimated will occur 24 months after the first patient is randomized</time_frame>
    <description>the percentage of patients with a complete or partial response of any duration or stable disease lasting ≥ 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>12 months after the date of randomization of the last patient, which is estimated will occur 24 months after the first patient is randomized</time_frame>
    <description>the period from the date of randomization to the date when disease progression is first documented or when the patient dies within 6 weeks of the last lesion assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival rate</measure>
    <time_frame>6 and 12 months after patients' date of randomization</time_frame>
    <description>the percentage of patients who are progression free</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to 30 days after patients' last dose of study medication</time_frame>
    <description>the percentage of patients with adverse events classified by term and body system</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">213</enrollment>
  <condition>Locally Advanced Non-resectable Breast Cancer</condition>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Tesetaxel every 3 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tesetaxel 27 mg/m2 orally on Day 1 in a 21-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tesetaxel weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks on Day 1, Day 8, and Day 15 in a 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capecitabine 1250 mg/m2 orally twice daily (equivalent to a total daily dose of 2500 mg/m2) on Day 1 through Day 14 in a 21-day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tesetaxel</intervention_name>
    <description>Tesetaxel 27 mg/m2 orally once on Day 1 of each 21-day cycle</description>
    <arm_group_label>Tesetaxel every 3 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tesetaxel</intervention_name>
    <description>Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks on Day 1, Day 8, and Day 15 of each 28-day cycle</description>
    <arm_group_label>Tesetaxel weekly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 1250 mg/m2 orally twice daily (in the morning and evening after a meal; equivalent to a total daily dose of 2500 mg/m2) on Day 1 through Day 14 of each 21-day cycle</description>
    <arm_group_label>Capecitabine</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion criteria:&#xD;
&#xD;
          1. Female&#xD;
&#xD;
          2. At least 18 years of age&#xD;
&#xD;
          3. Locally advanced non-resectable or metastatic breast cancer&#xD;
&#xD;
          4. HER2 negative disease&#xD;
&#xD;
          5. Measurable disease per revised RECIST, Version 1.1&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group performance status 0 or 1&#xD;
&#xD;
          7. Chemotherapy naïve, OR 1 prior chemotherapy regimen in the neoadjuvant or adjuvant&#xD;
             setting provided the patient has had a disease-free interval of ≥ 12 months after&#xD;
             ending this chemotherapy. If the neoadjuvant or adjuvant chemotherapy included a&#xD;
             taxane, ≥ 2 years must have passed since this treatment ended.&#xD;
&#xD;
          8. Documented disease recurrence or progression&#xD;
&#xD;
          9. Adequate bone marrow, hepatic, and renal function&#xD;
&#xD;
         10. Ability to swallow an oral solid-dosage form of medication&#xD;
&#xD;
         11. Written informed consent&#xD;
&#xD;
        Key exclusion criteria:&#xD;
&#xD;
          1. Known metastasis to the central nervous system&#xD;
&#xD;
          2. Other cancer within the preceding 5 years other than curatively treated basal or&#xD;
             squamous cell carcinoma of the skin or carcinoma of the cervix in situ&#xD;
&#xD;
          3. Significant medical disease other than breast cancer&#xD;
&#xD;
          4. Presence of neuropathy &gt; Grade 1 (NCI CTC)&#xD;
&#xD;
          5. History of hypersensitivity to a taxane or capecitabine, other fluoropyrimidine&#xD;
             agents, or any of their ingredients&#xD;
&#xD;
          6. History of severe or unexpected reaction to fluoropyrimidine therapy&#xD;
&#xD;
          7. Need to continue any regularly-taken medication that is a potent inhibitor or inducer&#xD;
             of the CYP3A pathway&#xD;
&#xD;
          8. Less than 2 weeks since use of a medication or ingestion of an agent, beverage, or&#xD;
             food that is a potent inhibitor or inducer of the CYP3A pathway&#xD;
&#xD;
          9. Known dihydropyrimidine dehydrogenase deficiency&#xD;
&#xD;
         10. Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew D Seidman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The West Clinic</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy B Stewart, RN, BSN, OCN, CCRC</last_name>
      <phone>901 683-0055</phone>
      <phone_ext>1236</phone_ext>
      <email>tstewart@WESTCLINIC.com</email>
    </contact>
    <investigator>
      <last_name>Lee S Schwartzberg, MD, FACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>May 25, 2012</study_first_submitted>
  <study_first_submitted_qc>May 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2012</study_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

